monarchE vs. PALLAS Data on Adjuvant ET in HR+ EBC: What Makes the Clinical Difference Between CDK4/6 Inhibitors Abemaciclib & Palbociclib? | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

CECOG Academy

monarchE vs. PALLAS Data on Adjuvant ET in HR+ EBC: What Makes the Clinical Difference Between CDK4/6 Inhibitors Abemaciclib & Palbociclib?

By CECOG Academy FEATURING Ahmad Awada

By CECOG Academy FEATURING Ahmad Awada

641 views

March 29, 2021

This video was completed prior to Abemaciclib receiving FDA approval on 10/12/21

Comments 0

Login to view comments. Click here to Login